Tomasz Sablinski
See the following -
Chip Away At The Stone: REMOTE, Transparency Life Sciences
(This blog is part 2 of my interview with Tomasz Sablinski, MD, PhD, Founder and CEO of Transparency Life Sciences. As noted in my first blog, Sablinski’s company announced it was the first company to have an IND cleared using a crowdsourced protocol. [...] Read More »
- Login to post comments
FDA Clears IND For First Clinical Trial Protocol Developed Using Crowdsourcing
Transparency Life Sciences, LLC (TLS), the world's first drug development company based on open innovation, today announced that its Investigational New Drug Application (IND) to assess lisinopril as an adjunctive therapy for multiple sclerosis (MS) has been cleared by the US Food and Drug Administration (FDA). Read More »
- Login to post comments
Let’s Build A Drug! Biopharma Startup Launches Crowdsourcing Tool To Pick Compounds
A biopharma startup believes that when it comes to deciding what conditions it should develop drugs to treat, the decision should be left to a public vote. Read More »
- Login to post comments
Re-thinking Clinical Trials For The World Of Crowdsourcing
Disruption isn’t a word normally associated with clinical drug development, but nevertheless it is coming. [...] There are signals that drug development is starting to catch up with the general trend toward open collaboration and innovation. This trend is enabling tremendous advances in other industries, so why not ours? Read More »
- Login to post comments
Transparency Life Sciences Awarded $1.4 Million NCATS SBIR Grant To Conduct Innovative Trial Of Lisinopril In Multiple Sclerosis
Transparency Life Sciences, LLC (TLS)...today announced that it has received a Small Business Innovation Research (SBIR) program grant to fund a Phase 2a proof-of-concept study testing the utility of the ACE inhibitor lisinopril as an adjunctive therapy for multiple sclerosis (MS).
- Login to post comments
Transparency Life Sciences Launches Indication Finder™ Crowdsourcing Tool For Drug Repurposing
Transparency Life Sciences (TLS), the world's first drug development company based on open innovation, today announced the launch of Indication Finder™, a survey-based crowdsourcing tool designed to identify promising new indications for existing drug candidates. Read More »
- Login to post comments
Trial Designed With Crowd Input Gets FDA Signoff
What's been called the first clinical study protocol developed using crowdsourcing methods received the FDA's imprimatur earlier this month. The agency approved Transparency Life Sciences' IND for a clinical trial designed to test a generic blood-pressure medication, ACE inhibitor lisinopril, in patients with relapsing remitting multiple sclerosis. Read More »
- Login to post comments